牛牛AI助理已提取核心訊息
AbbVie, a global biopharmaceutical company, reported its 2023 financial results with worldwide net revenues of $54.3 billion, a decrease of 6% from the previous year, attributed to Humira biosimilar competition. Operating earnings were $12.8 billion, and diluted earnings per share stood at $2.72. The company generated $22.8 billion in cash flows from operations. Despite the decline in Humira sales, growth was seen across the non-Humira product portfolio. AbbVie's business development included a diversified product portfolio with leadership in immunology, oncology, aesthetics, neuroscience, and eye care. The company's strategic objectives for 2024 focus on maximizing diversified revenue, strong commercial execution, pipeline investment, and returning cash to shareholders. Future plans involve regulatory submissions, clinical trial data readouts, and integration of recent acquisitions ImmunoGen, Inc. and Cerevel...Show More
AbbVie, a global biopharmaceutical company, reported its 2023 financial results with worldwide net revenues of $54.3 billion, a decrease of 6% from the previous year, attributed to Humira biosimilar competition. Operating earnings were $12.8 billion, and diluted earnings per share stood at $2.72. The company generated $22.8 billion in cash flows from operations. Despite the decline in Humira sales, growth was seen across the non-Humira product portfolio. AbbVie's business development included a diversified product portfolio with leadership in immunology, oncology, aesthetics, neuroscience, and eye care. The company's strategic objectives for 2024 focus on maximizing diversified revenue, strong commercial execution, pipeline investment, and returning cash to shareholders. Future plans involve regulatory submissions, clinical trial data readouts, and integration of recent acquisitions ImmunoGen, Inc. and Cerevel Therapeutics. AbbVie anticipates growth driven by products like Skyrizi and Rinvoq, and aims to manage Humira biosimilar erosion. The company's R&D pipeline includes approximately 90 compounds or indications, with significant developments in immunology and oncology. AbbVie's financial position remains strong, with a commitment to a robust dividend, evidenced by an increase in the quarterly cash dividend to $1.55 per share.
全球生物製藥公司艾伯維公佈了其2023年財務業績，全球淨收入爲543億美元，比上年下降6％，這要歸因於Humira生物仿製藥的競爭。營業收益爲128億美元，攤薄後每股收益爲2.72美元。該公司從運營中產生了228億美元的現金流。儘管Humira的銷售額有所下降，但非Humira產品組合仍出現增長。艾伯維的業務發展包括多元化的產品組合，在免疫學、腫瘤學、美學、神經科學和眼部護理方面處於領先地位。該公司2024年的戰略目標側重於最大限度地提高多元化收入、強勁的商業執行、管道投資以及向股東返還現金。未來的計劃包括監管機構提交、臨床試驗數據讀取以及最近收購的ImmunoGen, Inc.和Cereve...展開全部
全球生物製藥公司艾伯維公佈了其2023年財務業績，全球淨收入爲543億美元，比上年下降6％，這要歸因於Humira生物仿製藥的競爭。營業收益爲128億美元，攤薄後每股收益爲2.72美元。該公司從運營中產生了228億美元的現金流。儘管Humira的銷售額有所下降，但非Humira產品組合仍出現增長。艾伯維的業務發展包括多元化的產品組合，在免疫學、腫瘤學、美學、神經科學和眼部護理方面處於領先地位。該公司2024年的戰略目標側重於最大限度地提高多元化收入、強勁的商業執行、管道投資以及向股東返還現金。未來的計劃包括監管機構提交、臨床試驗數據讀取以及最近收購的ImmunoGen, Inc.和Cerevel Therapeutics的整合。艾伯維預計，增長將由Skyrizi和Rinvoq等產品推動，旨在管理Humira生物仿製藥的侵蝕。該公司的研發管道包括約90種化合物或適應症，在免疫學和腫瘤學方面取得了重大進展。艾伯維的財務狀況仍然強勁，承諾派發強勁的股息，季度現金分紅增加至每股1.55美元就證明了這一點。
有用
沒用